Profil
Michael Yeadon is the founder of Ziarco Pharma Ltd.
founded in 2012.
He previously held positions as President & Chief Executive Officer at Ziarco Group Ltd., Director at Antegrin Therapeutics LLC and Indalo Therapeutics, Inc., Chief Scientific Officer at Apellis Pharmaceuticals, Inc., Chief Scientific Officer & Vice President at Pfizer (St. Louis), and Senior Principal Scientist at Wellcome Research Laboratories.
Yeadon earned an undergraduate degree in 1985 and a doctorate in 1988 from the University of Surrey.
Anciens postes connus de Michael Yeadon
| Sociétés | Poste | Fin |
|---|---|---|
Ziarco Group Ltd.
 Ziarco Group Ltd. Pharmaceuticals: MajorHealth Technology Ziarco Group Ltd. operates as a clinical-stage biotechnology company that develops therapeutics targeting inflammatory skin diseases. The firm engages in development of novel treatments in dermatology. The company was incorporated on March 10, 2014 and is headquartered in Canterbury, the United Kingdom. | Directeur Général | 30/03/2016 |
Indalo Therapeutics, Inc.
 Indalo Therapeutics, Inc. BiotechnologyHealth Technology Indalo Therapeutics, Inc. operates as a biopharmaceutical firm that develops integrin antagonists for patients suffering from serious fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). The company was founded by David Griggs, Williamson Z. Bradford III, Peter Ruminski, and Robert W. Karr and is headquartered in Cambridge, MA. | Directeur/Membre du Conseil | - |
Antegrin Therapeutics LLC
 Antegrin Therapeutics LLC Pharmaceuticals: MajorHealth Technology Antegrin Therapeutics LLC develops novel therapies for fibrotic diseases. It focuses on idiopathic pulmonary fibrotic diseases, which are conditions that involve out-of-control scarring of organs. The company was founded by David Griggs and Peter Ruminski in 2012 and is headquartered in St. Louis, MO. | Directeur/Membre du Conseil | - |
Pfizer (St. Louis)
 Pfizer (St. Louis) BiotechnologyHealth Technology Part of Pfizer Inc., Pfizer (St. Louis) is a company that provides research services in prescription medicines for humans and animals. The company is based in Chesterfield, MO. | Directeur Technique/Scientifique/R&D | - |
| APELLIS PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | - |
Formation de Michael Yeadon
| University of Surrey | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| APELLIS PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
Ziarco Pharma Ltd.
 Ziarco Pharma Ltd. BiotechnologyHealth Technology Ziarco Pharma Ltd. provides therapeutics targeting inflammatory and allergic diseases. It focuses on chronic inflammatory skin diseases, atopic dermatitis, and Psoriasis. The company was founded by Michael Yeadon, Wai Leung Liu, Lynn Worth Purkins and Arif Kassam Shivji in 2012 and is headquartered in Sandwich, the United Kingdom. | Health Technology |
| Wellcome Research Laboratories | |
Pfizer (St. Louis)
Pfizer (St. Louis) BiotechnologyHealth Technology Part of Pfizer Inc., Pfizer (St. Louis) is a company that provides research services in prescription medicines for humans and animals. The company is based in Chesterfield, MO. | Health Technology |
Ziarco Group Ltd.
Ziarco Group Ltd. Pharmaceuticals: MajorHealth Technology Ziarco Group Ltd. operates as a clinical-stage biotechnology company that develops therapeutics targeting inflammatory skin diseases. The firm engages in development of novel treatments in dermatology. The company was incorporated on March 10, 2014 and is headquartered in Canterbury, the United Kingdom. | Health Technology |
Antegrin Therapeutics LLC
Antegrin Therapeutics LLC Pharmaceuticals: MajorHealth Technology Antegrin Therapeutics LLC develops novel therapies for fibrotic diseases. It focuses on idiopathic pulmonary fibrotic diseases, which are conditions that involve out-of-control scarring of organs. The company was founded by David Griggs and Peter Ruminski in 2012 and is headquartered in St. Louis, MO. | Health Technology |
Indalo Therapeutics, Inc.
Indalo Therapeutics, Inc. BiotechnologyHealth Technology Indalo Therapeutics, Inc. operates as a biopharmaceutical firm that develops integrin antagonists for patients suffering from serious fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). The company was founded by David Griggs, Williamson Z. Bradford III, Peter Ruminski, and Robert W. Karr and is headquartered in Cambridge, MA. | Health Technology |
